Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 14/20 | 0.43 |
| ▸ | PPARA | Q07869 | 13/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16939764 | 0.88 | LMNA (0.42) | HTTLMNAMAPK1L3MBTL1PPARG | |
| SCHEMBL16939758 | 0.84 | LMNA (0.41) | HTTLMNAMAPK1L3MBTL1PPARG | |
| SCHEMBL16939760 | 0.82 | NPC1 (0.42) | HTTLMNAMAPK1L3MBTL1NPC1 | |
| SCHEMBL16939763 | 0.81 | LMNA (0.44) | HTTLMNAMAPK1L3MBTL1PPARG | |
| SCHEMBL9449576 | 0.79 | KDM4E (0.53) | HTTLMNAMAPK1L3MBTL1PPARG | |
| SCHEMBL26714161 | 0.79 | L3MBTL1 (0.49) | HTTLMNAMAPK1L3MBTL1PPARG | |
| SCHEMBL9449579 | 0.79 | KDM4E (0.53) | HTTLMNAMAPK1L3MBTL1PPARG | |
| SCHEMBL8469074 | 0.78 | PPARG (0.51) | HTTLMNAMAPK1L3MBTL1PPARG | |
| SCHEMBL16939765 | 0.76 | HTT (0.45) | HTTLMNAL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL16939761 | 0.76 | CASP3 (0.43) | HTTLMNAMAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | F2R, F2RL1, F2RL3 | HTT 1034/4885LMNA 1577/4885MAPK1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.